| abstract |
The present invention relates to a benzoxazepine derivative having the general formula I, wherein X represents CO or SO2; R1, R2, R3 and R4 are independently selected from H, (C1-C4) alkyl, (C1-C4) alkyloxy, (C1-C4) alkyloxy (C1-C4), halogen, nitro, cyano, NR8R9, NR8COR10 and CONR8R9, R5, R6 and R7 are independently H or (C1-C4) alkyl; or R8 and R9 form together with the nitrogen atom to which a saturated heterocyclic ring, consisting of 5 or 6 members, is attached, which optionally contains an additional heteroatom selected from O, S or NR11; R10 is (C1-C4) alkyl; R11 is (C1-C4) alkyl; A represents the residue of a saturated heterocyclic ring, consisting of 4-7 members, optionally containing an oxygen atom, the ring being optionally substituted with 1-3 substitutes selected from alkyl (C1-C4), alkyloxy (C1-C4) ), hydroxy, halogen, and oxo; or a pharmaceutically acceptable salt thereof. The invention also relates to pharmaceutical compositions comprising said derivatives and the use of these benzoxazepine derivatives in the treatment of neurological diseases and psychiatric disorders that are responsive to the increase of synaptic responses mediated by AMPA receptors in the central nervous system. |